The panelists share their excitement about the future of glomerulonephritis therapies. The panel discusses the logistics of implementing the new treatments for C3G and IC-MPGN. The panel discusses the role of kidney biopsies in the clinical trials of iptacopan and pegcetacoplan for C3G. Our panel discusses two recently approved treatments, iptacopan for C3G and pegcetacoplan for C3G and IC-MPGN. Our panel discusses the history of C3G/IC-MPGN, the heterogeneity of glomerulonephritis, and new disease definitions.